JP2019521312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521312A5 JP2019521312A5 JP2018554537A JP2018554537A JP2019521312A5 JP 2019521312 A5 JP2019521312 A5 JP 2019521312A5 JP 2018554537 A JP2018554537 A JP 2018554537A JP 2018554537 A JP2018554537 A JP 2018554537A JP 2019521312 A5 JP2019521312 A5 JP 2019521312A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- clever
- patient
- tnf
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022020859A JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20165336 | 2016-04-18 | ||
| FI20165336 | 2016-04-18 | ||
| PCT/FI2017/050286 WO2017182706A1 (en) | 2016-04-18 | 2017-04-18 | Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020859A Division JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521312A JP2019521312A (ja) | 2019-07-25 |
| JP2019521312A5 true JP2019521312A5 (https=) | 2020-03-05 |
| JP7100588B2 JP7100588B2 (ja) | 2022-07-13 |
Family
ID=58692521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554537A Active JP7100588B2 (ja) | 2016-04-18 | 2017-04-18 | Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断 |
| JP2022020859A Active JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020859A Active JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10884000B2 (https=) |
| EP (1) | EP3445786B1 (https=) |
| JP (2) | JP7100588B2 (https=) |
| KR (1) | KR102403660B1 (https=) |
| CN (1) | CN109153720B (https=) |
| AU (1) | AU2017252344B2 (https=) |
| BR (1) | BR112018070350A2 (https=) |
| CA (1) | CA3020418A1 (https=) |
| EA (1) | EA201892313A1 (https=) |
| WO (1) | WO2017182706A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210087454A (ko) | 2018-11-01 | 2021-07-12 | 파론 파머수티컬스 오와이 | 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제 |
| US20220404366A1 (en) * | 2019-11-11 | 2022-12-22 | Faron Pharmaceuticals Oy | Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment |
| WO2021214382A1 (en) * | 2020-04-20 | 2021-10-28 | Faron Pharmaceuticals Oy | Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor |
| US20220227858A1 (en) | 2021-01-18 | 2022-07-21 | Faron Pharmaceuticals Oy | Controlling of immune activation by soluble clever-1 |
| JP2024545101A (ja) * | 2021-12-07 | 2024-12-05 | ファロン ファーマシューティカルズ オサケ ユキチュア | 抗ｃｌｅｖｅｒ－１がん治療を誘導するための炎症マーカーの使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60316106T2 (de) * | 2002-01-09 | 2008-05-29 | Faron Pharmaceuticals Oy | Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung |
| FI20090161A0 (fi) | 2009-04-22 | 2009-04-22 | Faron Pharmaceuticals Oy | Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä |
| SG11201502827RA (en) | 2012-11-09 | 2015-05-28 | Transgene Sa | Modulation of monocytes, or precursors thereof, differentiation |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
-
2017
- 2017-04-18 US US16/093,349 patent/US10884000B2/en active Active
- 2017-04-18 WO PCT/FI2017/050286 patent/WO2017182706A1/en not_active Ceased
- 2017-04-18 BR BR112018070350-8A patent/BR112018070350A2/pt not_active Application Discontinuation
- 2017-04-18 EA EA201892313A patent/EA201892313A1/ru unknown
- 2017-04-18 JP JP2018554537A patent/JP7100588B2/ja active Active
- 2017-04-18 AU AU2017252344A patent/AU2017252344B2/en active Active
- 2017-04-18 EP EP17722487.0A patent/EP3445786B1/en active Active
- 2017-04-18 CN CN201780024373.4A patent/CN109153720B/zh active Active
- 2017-04-18 CA CA3020418A patent/CA3020418A1/en active Pending
- 2017-04-18 KR KR1020187028561A patent/KR102403660B1/ko active Active
-
2022
- 2022-02-14 JP JP2022020859A patent/JP7302049B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521312A5 (https=) | ||
| Thiebaud et al. | Muscle damage after low-intensity eccentric contractions with blood flow restriction | |
| Rossi et al. | Identifying sarcopenia in acute care setting patients | |
| Brandner et al. | Unilateral bicep curl hemodynamics: low‐pressure continuous vs high‐pressure intermittent blood flow restriction | |
| Tandon et al. | Unraveling links between chronic inflammation and long COVID: workshop report | |
| JP2016118568A5 (https=) | ||
| JP2017509374A5 (https=) | ||
| JP2019503824A5 (https=) | ||
| JP2008536618A5 (https=) | ||
| JP2012505012A5 (https=) | ||
| Tibana et al. | Women with metabolic syndrome present different autonomic modulation and blood pressure response to an acute resistance exercise session compared with women without metabolic syndrome | |
| MX2020008291A (es) | Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos. | |
| Daniel et al. | Comparison of inter-canine and inter-molar width as an aid in gender determination: A preliminary study | |
| JP2013094261A5 (https=) | ||
| Janson et al. | Interlabial gap behavior with time | |
| RMFM | Fleming inflammation and cardiovascular disease SARS‑CoV‑2 proposed treatment protocol. Initial COVID hydroxychloroquine failure responds to interferon α‑2β and tocilizumab | |
| Williams et al. | Research methods: translational research in geriatric oncology | |
| Öhman | Visualizing congestion with ultrasound: diagnostic and therapeutic implications | |
| Teng et al. | Study on the responses of hypertensive patients to music | |
| CN202563512U (zh) | 医疗诊断数据管理系统 | |
| JP2018181352A5 (https=) | ||
| Sahoo et al. | Effect of exercise on nerve conduction study of Carpal tunnel syndrome patients | |
| Sharma et al. | Zoledronic acid and bisphosphonate related osteonecrosis of the jaw | |
| Karagiannis et al. | A61 LUNG FIBROSIS: ANIMAL MODELS II: Activin A And Follistatin Like-3 Levels In Bronchoalveolar Lavage Fluid Of Patients With Systemic Sclerosis Related Interstitial Lung Disease | |
| TWM496455U (zh) | 血管彈性檢測裝置 |